| GTO ID | GTC2898 |
| Trial ID | NCT05198752 |
| Disease | Solid Tumor |
| Therapy | mRNA vaccine |
| Treatment | SW1115C3 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours |
| Year | 2022 |
| Country | Australia|Austria|Belgium|Canada|Czechia|France|Germany|NewZealand|Spain|UnitedKingdom|UnitedStates |
| Company sponsor | Stemirna Therapeutics |
| Other ID(s) | SWP1001-06 |
| Cohort 1 | |||||||
|
|||||||